ENDPOINTS NEWS35m
Paris start­up col­lects €27M in Se­ries B to ad­vance over­ac­tive blad­der treat­ment
A French biotech focused on developing genetic medicines for neurological conditions has secured €27 million in a Series B ...
ENDPOINTS NEWS57m
Can amylin drugs take over from GLP-1s in obe­si­ty? Part­ner­less Zealand thinks so
Zealand Pharma reports 2024 results but no partnering deal for petrelintide. CEO Adam Steensberg remains confident despite ...